Advanced or Metastatic Solid Tumors
72
14
25
24
Key Insights
Highlights
Success Rate
60% trial completion
Published Results
12 trials with published results (17%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
22.2%
16 terminated out of 72 trials
60.0%
-26.6% vs benchmark
0%
0 trials in Phase 3/4
50%
12 of 24 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 24 completed trials
Clinical Trials (72)
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors
A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase I Study of Single-Agent KGX105 in Patients With Advanced or Metastatic Solid Tumors
A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)
A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors